Key Events This Week
1 June: Downgrade to Strong Sell by MarketsMOJO
3 June: Stock hits 52-week low of Rs.1.65
5 June: Week closes at Rs.1.80, up 3.45% for the week

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.52 as Sell-Off Deepens
2026-06-10 10:37:32A sharp decline of 13.14% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.52 on 10 Jun 2026, marking a significant underperformance against its sector and the broader market.
Read full news article
Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.65 as Sell-Off Deepens
2026-06-03 10:36:24A sharp decline of 8.84% today dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.65, extending its downward trajectory despite recent positive quarterly results. This drop comes amid broader market weakness, with the Sensex also falling sharply, but the stock’s underperformance remains pronounced.
Read full news article
Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Concerns
2026-06-02 08:46:08Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This adjustment reflects deteriorating technical indicators, persistent operating losses, and underwhelming long-term financial trends despite recent positive quarterly results.
Read full news articleVivanza Biosciences Declines 1.69% Amid Mixed Technical Signals and Financial Challenges
2026-05-30 17:06:31
Key Events This Week
25 May: Stock opens steady at Rs.1.77 with no price change
26 May: Rating upgraded to Sell by MarketsMOJO on technical improvements
27 May: Stock dips 1.13% to Rs.1.75 amid mixed market signals
29 May: New 52-week low of Rs.1.74 recorded, closing the week down 1.69%
Announcement under Regulation 30 (LODR)-Newspaper Publication
08-Aug-2026 | Source : BSEin the terms of Regulation 47 of the SEBI(LODR) Regulation 2015 Please find the copy of the Newspaper in the English and vernacular Language of the State wherein the Unaudited Standalone and Consolidated Financial Statements for the Quarter Ended on June 30 2026 Published.
Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI LODR Regulations 2015
08-Aug-2026 | Source : BSEPursuant to Regulation 32 of the SEBI(LODR) Regulation 2015 Read with SEBI circular dated 24th December 2019 regarding the submission of the statement of deviation or variation from the proceeds of public issue/rights issue/preferential issue qualified institutional placement etc. we hereby confirm that the company has not raised any further funds by means of Public Issue rights issue or preferential issue etc. hence the statement of deviation and variation is not applicable to the company.
Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited (The Company)
07-Aug-2026 | Source : BSEApproval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and other items .
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
Vivanza Biosciences Ltd has announced 1:10 stock split, ex-date: 24 Mar 23
No Bonus history available
No Rights history available









